ENDRA Life Sciences Inc.

US$4.73As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NDRAHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR (66.63%)
Div yield —
ROE (152.04%)
Diagnostics & Research
Beta (5Y) (0.11)
PE TTM —
TSR TTM (9.90%)
Mkt cap US$7.094M
ROIC (94.78%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.01
5.97%
(76.96%)
Hold 0|2|6|6|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.11
0.12
0.12
0.11
15.17%
23.09%
19.87%
11.34%
Revenue$M
0.355
0.369
0.382
0.383
6.17%
8.32%
14.97%
10.52%
Peers (US$7.094M)
Cap (US$)
PE
5.055M
—
2.051M
—
Capital
TTM
5Y
10Y
Leveragex
8.418
0.190
0.172
EBIT/Intx
2.144
0.532
0.506
Own earn%
57.22
(103.36)
(59.03)
Sh yield%
13.04
45.89
42.72
Owners
Insiders/Inst%
0.23
58.83
Short interest%
2.92
SBC / revenue%
0.74
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
18–22
$1 testx
—
Incr. ROIC%
6